Pfizer Inc (NYSE:PFE)’s traded shares stood at 5.36 million during the latest session, with the company’s beta value hitting 0.63. At the last check today, the stock’s price was $26.50, to imply a decrease of -0.84% or -$0.22 in intraday trading. The PFE share’s 52-week high remains $31.54, putting it -19.02% down since that peak but still an impressive 4.91% since price per share fell to its 52-week low of $25.20. The company has a valuation of $150.15B, with an average of 49.58 million shares in intraday trading volume over the past 10 days and average of 33.26 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Pfizer Inc (PFE), translating to a mean rating of 2.19. Of 16 analyst(s) looking at the stock, 1 analyst(s) give PFE a Sell rating. 1 of those analysts rate the stock as Overweight while 7 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.47.

Pfizer Inc (NYSE:PFE) trade information

After registering a -0.84% downside in the latest session, Pfizer Inc (PFE) has traded red over the past five days. The 5-day price performance for the stock is -3.51%, and -10.70% over 30 days. With these gigs, the year-to-date price performance is -7.97%. Short interest in Pfizer Inc (NYSE:PFE) saw shorts transact 61.87 million shares and set a 1.83 days time to cover.

The extremes give us $20 and $70 for target low and target high price respectively. As such, PFE has been trading -164.15% off suggested target high and 24.53% from its likely low.

Pfizer Inc (PFE) estimates and forecasts

Looking at statistics comparing Pfizer Inc share performance against respective industry, we note that the company has outperformed competitors. Pfizer Inc (PFE) shares are -8.39% down over the last 6 months, with its year-to-date growth rate higher than industry average at 56.52% against 8.80%. Revenue is forecast to grow 372.33% this quarter before falling -10.53% for the next one. The rating firms project that company’s revenue will grow 7.19% compared to the previous financial year.

Revenue forecast for the current quarter as set by 16 analysts is 17.28B. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 14.34B.Earnings reports from the last fiscal year show that sales brought in 14.25B and 14.88B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 21.30% before dropping -3.65% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -27.43% for the past 5-year period. While 2024 is set for a 57.16% return in earnings, projections for the next 5 years are at 5.10% annually.

PFE Dividends

Pfizer Inc has its next earnings report out on 2025-Jan-28. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Pfizer Inc has a forward dividend ratio of 1.68, with the share yield ticking at 6.34% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 4.23%.

Pfizer Inc (NYSE:PFE)’s Major holders

Pfizer Inc insiders hold 0.05% of total outstanding shares, with institutional holders owning 67.86% of the shares at 67.90% float percentage. In total, 67.86% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 511.4 million shares (or 9.0402% of shares), all amounting to roughly $14.31 billion.

The next major institution holding the largest number of shares is BLACKROCK INC. with 424.38 million shares, or about 7.5018% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.87 billion.